EGFR and ovarian carcinoma: The success in other cancer types of alternative biomarkers, including activated proteins downstream of EGFR signaling, EGFR mutations and mutations in other pathway genes, may suggest more fruitful directions for identifying potential surrogate markers of EGFR expression, activation, and treatment response in ovarian cancer.